Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon

Gastroenterology

Volumn 142, Issue 5, 2012, Pages

  Levitsky, Josh ^a   Fiel, Maria Isabel ^b   Norvell, John P ^a   Wang, Edward ^a   Watt, Kymberly D ^c   Curry, Michael P ^d   Tewani, Sumeet ^d   McCashland, Timothy M ^e   Hoteit, Maarouf A ^f   Shaked, Abraham ^f   Saab, Samuel ^g   Chi, Amanda C ^g   Tien, Amy ^b   Schiano, Thomas D ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c MAYO CLINIC ROCHESTER   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immune Response; Immunosuppression; Organ Transplantation; Viral Hepatitis

Indexed keywords

ALKALINE PHOSPHATASE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHRONIC GRAFT REJECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HEPATITIS; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNE MEDIATED GRAFT DYSFUNCTION; IMMUNOPATHOLOGY; LIVER BIOPSY; LIVER CELL; LIVER GRAFT; LIVER GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PLASMA CELL HEPATITIS; PRIORITY JOURNAL; RECURRENCE RISK; RETRANSPLANTATION; SURVIVAL; TREATMENT OUTCOME;

EID: 84860224685     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2012.01.030     Document Type: Article

References (34)

1. E.J. Gane, B.C. Portmann, N.V. Naoumov Long-term outcome of hepatitis C infection after liver transplantation N Engl J Med 334 1996 815 820
2. M. Prieto, M. Berenguer, J.M. Rayon High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes Hepatology 29 1999 250 256
3. L.M. Forman, J.D. Lewis, J.A. Berlin The association between hepatitis C infection and survival after orthotopic liver transplantation Gastroenterology 122 2002 889 896
4. C.S. Wang, H.H. Ko, E.M. Yoshida Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis Am J Transplant 6 2006 1586 1599
5. S. Yedibela, D. Schuppan, V. Muller Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation Liver Int 25 2005 717 722
6. T. Papo, P. Marcellin, J. Bernuau Autoimmune chronic hepatitis exacerbated by alpha-interferon Ann Intern Med 116 1992 51 53
7. D. Preziati, L. La Rosa, G. Covini Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a Eur J Endocrinol 132 1995 587 593
8. S. Berardi, F. Lodato, A. Gramenzi High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 56 2007 237 242
9. N. Kontorinis, K. Agarwal, N. Elhajj Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation Liver Transpl 12 2006 827 830
10. M.I. Fiel, K. Agarwal, C. Stanca Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus Liver Transpl 14 2008 861 871
11. S.C. Ward, T.D. Schiano, S.N. Thung Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant Liver Transpl 15 2009 1826 1833
12. C.M. Stanca, M.I. Fiel, N. Kontorinis Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin Transplantation 84 2007 180 186
13. N. Selzner, M. Guindi, E.L. Renner Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients J Hepatol 55 2011 207 217
14. A. Demetris, D. Adams, C. Bellamy Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection An international panel Hepatology 31 2000 792 799
15. Banff schema for grading liver allograft rejection: an international consensus document Hepatology 25 1997 658 663
16. D.A. Schoenfeld Sample-size formula for the proportional-hazards regression model Biometrics 39 1983 499 503
17. M. Berenguer, A. Palau, A. Fernandez Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C Liver Transpl 12 2006 1067 1076
18. F.P. Picciotto, G. Tritto, A.G. Lanza Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation J Hepatol 46 2007 459 465
19. M. Berenguer, A. Palau, V. Aguilera Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation Am J Transplant 8 2008 679 687
20. H. Hofer, C. Oesterreicher, F. Wrba Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation J Clin Pathol 59 2006 246 249
21. R.T. Stravitz, J.H. Lefkowitch, R.J. Fontana Autoimmune acute liver failure: proposed clinical and histological criteria Hepatology 53 2011 517 526
22. T. Awad, K. Thorlund, G. Hauser Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials Hepatology 51 2010 1176 1184
23. D.A. Neil, S.G. Hubscher Histologic and biochemical changes during the evolution of chronic rejection of liver allografts Hepatology 35 2002 639 651
24. M.L. Shiffman, M.J. Contos, V.A. Luketic Biochemical and histologic evaluation of recurrent hepatitis C following orthotopic liver transplantation Transplantation 57 1994 526 532
25. M. Berenguer, V. Aguilera, M. Prieto Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression J Hepatol 44 2006 717 722
26. S.M. Kamal, J. Fehr, B. Roesler Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C Gastroenterology 123 2002 1070 1083
27. H.R. Rosen, D.J. Hinrichs, D.R. Gretch Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation Gastroenterology 117 1999 926 932
28. T. Tatsumi, T. Takehara, T. Miyagi Hepatitis C virus-specific CD8+ T cell frequencies are associated with the responses of pegylated interferon-alpha and ribavirin combination therapy in patients with chronic hepatitis C virus infection Hepatol Res 41 2011 30 38
29. S.J. Weston, R.L. Leistikow, K.R. Reddy Reconstitution of hepatitis C virus-specific T-cellmediated immunity after liver transplantation Hepatology 41 2005 72 81
30. V. Tahan, F. Ozseker, D. Guneylioglu Sarcoidosis after use of interferon for chronic hepatitis C: report of a case and review of the literature Dig Dis Sci 48 2003 169 173
31. H. Tilg New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine Gastroenterology 112 1997 1017 1021
32. E. Larrea, N. Garcia, C. Qian Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C Hepatology 23 1996 210 217
33. M.I. Fiel, K. Agarwal, C. Stanca Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus Liver Transpl 14 2008 861 871
34. S.C. Ward, T.D. Schiano, S.N. Thung, M.I. Fiel Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant Liver Transpl 15 2009 1826 1833